223 related articles for article (PubMed ID: 38381173)
1. Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia.
Wang X; Zhang Y; Xue S
Ann Hematol; 2024 Jun; 103(6):1843-1857. PubMed ID: 38381173
[TBL] [Abstract][Full Text] [Related]
2. Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.
Pratap S; Zhao ZJ
Cancer Rep (Hoboken); 2020 Apr; 3(2):e1222. PubMed ID: 32671999
[TBL] [Abstract][Full Text] [Related]
3. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
4. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
Front Immunol; 2020; 11():580328. PubMed ID: 33384686
[TBL] [Abstract][Full Text] [Related]
6. Prospect of CAR T-cell therapy in acute myeloid leukemia.
Badar T; Manna A; Gadd ME; Kharfan-Dabaja MA; Qin H
Expert Opin Investig Drugs; 2022 Feb; 31(2):211-220. PubMed ID: 35051347
[TBL] [Abstract][Full Text] [Related]
7. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML).
Lu Y; Liu Y; Wen S; Kuang N; Zhang X; Li J; Wang F
J Transl Med; 2022 Dec; 20(1):600. PubMed ID: 36517851
[TBL] [Abstract][Full Text] [Related]
8. Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia.
Wang XY; Bian MR; Lin GQ; Yu L; Zhang YM; Wu DP
Eur J Haematol; 2024 Jan; 112(1):83-93. PubMed ID: 37712633
[TBL] [Abstract][Full Text] [Related]
9. How close are we to CAR T-cell therapy for AML?
Gill SI
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101104. PubMed ID: 31779970
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia.
Wu G; Guo S; Luo Q; Wang X; Deng W; Ouyang G; Pu JJ; Lei W; Qian W
Front Immunol; 2023; 14():1093750. PubMed ID: 36845088
[TBL] [Abstract][Full Text] [Related]
11. Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy.
Zhao Y; Zhang X; Zhang M; Guo R; Zhang Y; Pu Y; Zhu H; Liu P; Zhang Y; He X; Lyu C; Lyu H; Xiao X; Zhao M
Ann Hematol; 2024 Mar; 103(3):969-980. PubMed ID: 38214708
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis.
Zhang H; Bu C; Peng Z; Li G; Zhou Z; Ding W; Zheng Y; He Y; Hu Z; Pei K; Luo M; Li C
Leukemia; 2022 Nov; 36(11):2596-2604. PubMed ID: 36151140
[TBL] [Abstract][Full Text] [Related]
14. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
[TBL] [Abstract][Full Text] [Related]
15. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
[TBL] [Abstract][Full Text] [Related]
16. [Current status and future perspective of CAR T-cell therapy for acute myeloid leukemia].
Nakazawa Y
Rinsho Ketsueki; 2022; 63(10):1446-1453. PubMed ID: 36351654
[TBL] [Abstract][Full Text] [Related]
17. Anti-CLL1 Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia.
Zhang H; Wang P; Li Z; He Y; Gan W; Jiang H
Clin Cancer Res; 2021 Jul; 27(13):3549-3555. PubMed ID: 33832948
[TBL] [Abstract][Full Text] [Related]
18. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
Morgan MA; Kloos A; Lenz D; Kattre N; Nowak J; Bentele M; Keisker M; Dahlke J; Zimmermann K; Sauer M; Heuser M; Schambach A
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372571
[TBL] [Abstract][Full Text] [Related]
19. Generation of Suicide Gene-Modified Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy.
Minagawa K; Al-Obaidi M; Di Stasi A
Methods Mol Biol; 2019; 1895():57-73. PubMed ID: 30539529
[TBL] [Abstract][Full Text] [Related]
20. CAR T-cells targeting FLT3 have potent activity against FLT3
Jetani H; Garcia-Cadenas I; Nerreter T; Thomas S; Rydzek J; Meijide JB; Bonig H; Herr W; Sierra J; Einsele H; Hudecek M
Leukemia; 2018 May; 32(5):1168-1179. PubMed ID: 29472720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
